Controlled Commercial Launch of Flexible, Irrigated Catheter Commences in Europe

MONMOUTH JUNCTION, NJ–(Marketwire – September 1, 2010) –  CytoSorbents Corporation (OTCBB: CTSO) David Lamadrid, Chief Financial Officer of CytoSorbents, has been named a finalist in the Public Company category in the ‘2010 NJBIZ CFO of the Year’ awards program. NJBIZ honors New Jersey’s top financial executives. The award program, produced by NJBIZ, New Jersey’s premiere business news publication, is presented by WithumSmith+Brown, PC and sponsored by CIGNA, Citibank, Financial Executives International, Robert Half and SorinRoyerCooper.

Controlled Commercial Launch of Flexible, Irrigated Catheter Commences in Europe

MONMOUTH JUNCTION, NJ–(Marketwire – September 1, 2010) –  CytoSorbents Corporation (OTCBB: CTSO) David Lamadrid, Chief Financial Officer of CytoSorbents, has been named a finalist in the Public Company category in the ‘2010 NJBIZ CFO of the Year’ awards program. NJBIZ honors New Jersey’s top financial executives. The award program, produced by NJBIZ, New Jersey’s premiere business news publication, is presented by WithumSmith+Brown, PC and sponsored by CIGNA, Citibank, Financial Executives International, Robert Half and SorinRoyerCooper.

ALEXANDRIA, VA–(Marketwire – September 1, 2010) – Close to 50 million Americans each year still struggle to access the health care services they need. We will not achieve health equity in the United States until each person has the opportunity to attain their full potential and no one is disadvantaged simply because of socially determined circumstances. MarbleRoad is here to help improve access to quality, affordable health care services for rare disease patients and community health center patients who require specialty care services not offered by their primary care providers.

ALEXANDRIA, VA–(Marketwire – September 1, 2010) – Close to 50 million Americans each year still struggle to access the health care services they need. We will not achieve health equity in the United States until each person has the opportunity to attain their full potential and no one is disadvantaged simply because of socially determined circumstances. MarbleRoad is here to help improve access to quality, affordable health care services for rare disease patients and community health center patients who require specialty care services not offered by their primary care providers.

MONMOUTH JUNCTION, NJ–(Marketwire – September 1, 2010) –  CytoSorbents Corporation (OTCBB: CTSO) David Lamadrid, Chief Financial Officer of CytoSorbents, has been named a finalist in the Public Company category in the ‘2010 NJBIZ CFO of the Year’ awards program. NJBIZ honors New Jersey’s top financial executives. The award program, produced by NJBIZ, New Jersey’s premiere business news publication, is presented by WithumSmith+Brown, PC and sponsored by CIGNA, Citibank, Financial Executives International, Robert Half and SorinRoyerCooper.

MANCHESTER, UNITED KINGDOM–(Marketwire – Sept. 2, 2010) – Epistem plc (LSE:EHP), the UK biotechnology company, announced today that its Contract Research Services division has entered into an agreement with the Veritas Corporation to exclusively market and distribute Epistem’s scientific research services in Japan.

ALEXANDRIA, VA–(Marketwire – September 1, 2010) – Close to 50 million Americans each year still struggle to access the health care services they need. We will not achieve health equity in the United States until each person has the opportunity to attain their full potential and no one is disadvantaged simply because of socially determined circumstances. MarbleRoad is here to help improve access to quality, affordable health care services for rare disease patients and community health center patients who require specialty care services not offered by their primary care providers.

MANCHESTER, UNITED KINGDOM–(Marketwire – Sept. 2, 2010) – Epistem plc (LSE:EHP), the UK biotechnology company, announced today that its Contract Research Services division has entered into an agreement with the Veritas Corporation to exclusively market and distribute Epistem’s scientific research services in Japan.